A novel cell-based assay for the high-throughput screening of epithelial–mesenchymal transition inhibitors: Identification of approved and investigational drugs that inhibit epithelial–mesenchymal transition

Hiroyuki Ishikawa(Kyoto University), Hiroshi Date(Kyoto University)
Lung Cancer
November 23, 2022
10.1016/j.lungcan.2022.11.015
Cited by 2

Related Papers

Association between epithelial‐mesenchymal transition and cancer stemness and their effect on the prognosis of lung adenocarcinoma
|Cancer Medicine|2015|51
M2‐like tumor‐associated macrophages promote epithelial–mesenchymal transition through the transforming growth factor β/Smad/zinc finger e‐box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamous cell carcinoma
|Cancer Science|2023|30
Tranilast Inhibits TGF-β1–induced Epithelial-mesenchymal Transition and Invasion/Metastasis <i>via</i> the Suppression of Smad4 in Human Lung Cancer Cell Lines
|Anticancer Research|2020|28
The synergistic role of <scp>ATP</scp>‐dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer
|Cancer Medicine|2018|27
The novel compound PICCS improves cell viability during cold storage and reduces pulmonary ischemia-reperfusion injury in a rat model
|Scientific Reports|2025|1